|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 38/17 | |
| A61P 25/02 | |||
| A61K 38/00 |
| (11) | Number of the document | 2061485 |
| (13) | Kind of document | T |
| (96) | European patent application number | 07804199.3 |
| Date of filing the European patent application | 2007-09-10 | |
| (97) | Date of publication of the European application | 2009-05-27 |
| (45) | Date of publication and mention of the grant of the patent | 2012-08-22 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/GB2007/003401 |
| Date | 2007-09-10 |
| (87) | Number | WO 2008/029167 |
| Date | 2008-03-13 |
| (30) | Number | Date | Country code |
| 0617734 | 2006-09-08 | GB |
| (72) |
HAMER, John, GB
|
| (73) |
Varleigh Immuno Pharmaceuticals (VIP) Ltd,
Landmark Fiduciaire (Suisse) SA 6 Place des Eaux-Vives Case Postale 3461, 1211 Geneva 3,
CH
|
| (54) | EV576 peptides for use in the treatment of Guillain Barré syndrome |
| EV576 peptides for use in the treatment of Guillain Barré syndrome |